Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK4290 in newly diagnosed wAMD
NCT03558061Phase 2Completed
- Sponsor
- Alkahest, Inc.
- Start
- Apr 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BI 144807 in exudative macular degeneration, sponsored by Alkahest, Inc. Primary endpoint: Best Corrected Visual Acuity at 6 weeks. Started Apr 2018; status: completed.
02
Drugs
BI 144807
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT03558061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03558061.